MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis, LLC, a Memphis-based specialty biopharmaceutical company, has licensed a second treatment for Dry Eye Syndrome (DES) developed by researchers at the Southern College of Optometry (SCO) in Memphis. The licensed patent application covers the use of transdermal progesterone in the treatment of DES, a condition that affects at least 20 million people in the U.S. and over 100 million people worldwide. The license agreement for this new DES treatment follows arGentis’ earlier licensure of intellectual property covering the use of transdermal testosterone in the treatment of DES, which would be prescribed in menopausal women. Approximately 30% of menopausal women suffer from DES, due to waning androgen production.
